Singapore: French biopharmaceutical company, Poxel, an innovative drug developer for type 2 diabetes, has succesfully conculded phase 1 clinical trial of its lead candidate, Imeglimin, in Japan.

Dr Yohjiro Itoh has joined Poxel as vice president regulatory and clinical development Asia to lead the company's drug development and registration efforts in Asia.

"I am very excited to support Imeglimin Asian development after this innovative compound completed its phase 2b and is ready for phase 3 in the US and Europe and I look forward to contributing to Poxel's success in making Imeglimin available to the Asian markets."

"Japan, as with much of Asia, has an exponentially growing need for diabetes treatments. It is an attractive market for innovative company like Poxel, and we see great value in building a focused presence there," said Mr Thomas Kuhn, CEO, Poxel. "Combined with our promising phase 1 results for Imeglimin in Japanese subjects that will help accelerate Imeglimin development in this country, the addition of Dr Itoh to our team and his expertise and knowledge of the Japanese regulatory environment will be of great importance to Poxel over the next years as we expand our efforts in Asia."

Dr Yohjiro Itoh commented, "I am very excited to support Imeglimin Asian development after this innovative compound completed its phase 2b and is ready for phase 3 in the US and Europe and I look forward to contributing to Poxel's success in making Imeglimin available to the Asian markets."